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Abstract 
1. The therapeutic class of HMG-CoA reductase inhibitors, the statins, are central 
agents in the treatment of hypercholesterolemia, and the associated conditions of 
cardiovascular disease, obesity and metabolic syndrome. Whereas statin-therapy is 
generally considered safe a number of known adverse effects do occur, most 
commonly treatment associated-muscular pain.  
2. In vitro evidence also supports the potential for drug-drug interactions involving 
this class of agents, and to examine this a ligand-binding assay was used to 
determine the ability of six clinically used statins for their ability to directly activate 
the nuclear receptors PXR, FXR and CAR, demonstrating a relative activation of 
PXR>FXR>CAR.  
3. Using reporter gene constructs, we demonstrate this order of activation is mirrored 
at the transcriptional activation level, with PXR-mediated gene activation being pre-
eminent. Finally, we describe a novel regulatory loop, whereby activation of FXR by 
statins increases PXR reporter gene expression, potentially enhancing PXR-
mediated responses.  
4. Delineating the molecular interactions of statins with nuclear receptors is an 
important step in understanding the full biological consequences of statin exposure. 
This demonstration of their ability to directly activate nuclear receptors, leading to 
nuclear receptor cross-talk, has important potential implications for their use 
within a polypharmacy paradigm. 
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Introduction 
The HMG CoA reductase inhibitors, or statins, are front-line drugs for the treatment of 
hypercholestraemia, reducing mortality and morbidity associated with cardiovascular 
disease. They achieve their therapeutic action through the inhibition of HMG-CoA 
reductase, the rate limiting enzyme in the cholesterol biosynthesis pathway (Dietschy 
and Wilson 1970). This reduction in cholesterol synthesis is accompanied by an up-
regulation of LDL receptors on hepatocytes, resulting in increased LDL uptake, and thus 
cholesterol, from the systemic circulation. The combined effect of reducing de novo 
synthesis and the up-regulation of LDL receptors leads to a typical reduction in LDL 
cholesterol of 20-35% (Linsel-Nitschke and Tall 2005), although rosuvastatin, the most 
recently marketed compound in the statin class, has been reported to cause up to a 63% 
decrease (Olsson et al. 2001). Lipid lowering impacts positively on the stability of 
atherosclerotic plaques in blood vessels, probably by reducing plaque size/lipid 
composition, and as plaque rupture is a major cause of cardiovascular disease, this 
stabilisation reduces cardiovascular disease by around 30-35% (Linsel-Nitschke and 
Tall 2005).  
Simvastatin, lovastatin and pravastatin, which are all fungal-derived compounds, share 
very similar structures, although additional hydroxyl groups make pravastatin more 
hydrophilic than either simvastatin or lovastatin. By comparison, fluvastatin, 
pitavastatin, cerivastatin, atorvastatin and rosuvastatin are synthetically derived 
compounds, again sharing structural similarities, such as a common fluoride side group 
(Figure 1). In general, statins are administered in their active form, and are readily 
absorbed by passive diffusion. However, both simvastatin and lovastatin are 
administered as inactive lactone prodrugs, which are lipophilic, and hydrolysed to the 
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active β-hydroxyacid by intracellular esterases and paraoxonases  following absorption 
(Billeclke et al. 2000). 
An important functional difference within the statin family is their mode of metabolism: 
The majority of statins undergo cytochrome P450-mediated metabolism, predominantly 
through CYP3A4, while the increased hydrophilicity of pravastatin and rosuvastatin 
reduces the requirement for this, with the parent compound being efficiently excreted. 
The net result of this is altered pharmacokinetics for pravastatin and rosuvastatin 
compared to the remaining chemicals in this class (Everett et al. 1991): For example, 
upwards of 54 % of pravastatin is eliminated from the body as the parent compound, 
considerably higher than 20 % typically observed with other, more lipophilic, statins 
(Everett et al. 1991; Lennernas and Fager 1997). 
In general, statins are well tolerated, although treatment-dependent muscular pain is a 
relatively common side effect. In general this side effect can be mitigated through dose 
reduction (Sirvent et al. 2008), although in some cases it can progress to severe 
muscular toxicity (rhabdomyolysis), which requires cessation of treatment (Vaklavas et 
al. 2009). The probability of such adverse effects may be increased through alterations 
in statin pharmacokinetics caused via drug-drug interactions, with CYP3A4-metabolised 
statins being particularly susceptible victim drugs (Neuvonen et al. 2006). In addition, it 
has been reported that statins have the potential to induce CYP3A4  (El-Sankary et al. 
2001) and ABCB1 (Yamasaki et al. 2009) expression levels in vitro, and that this effect 
may extend to in vivo (Watanabe et al. 2004), suggesting that statins may act as 
perpetrators for drug-drug interactions as well as victims. Such interactions are 
presumed to occur through the activation of members of the nuclear receptor 
superfamily, which act as ligand-activated transcription factors regulating many aspects 
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of cellular metabolism (Plant and Aouabdi 2009). Indeed,  several statins have been 
identified as potential agonists for the pregnane X-receptor (PXR; NR1I2) (Raucy et al. 
2002; Wagner et al. 2005), the nuclear receptor that regulates CYP3A4 and ABCB1 gene 
expression (Plant 2007), as well as the constitutive androstane receptor (CAR; NR1I3 
(Kobayashi et al. 2005)). In addition, equivocal evidence exists to suggest that statins 
may activate other nuclear receptors, such as the farnesoid X-receptor (FXR; NR1H4): 
This interaction may occur either through direct agonism of FXR or through the 
pharmacological action of statins in altering bile acid levels, which act as ligands for FXR 
(Habeos et al. 2005; Rizzo et al. 2005).  
Herein, we use a ligand-binding assay to undertake the first comprehensive analysis of 
the potential for statins to activate the nuclear receptors PXR, its closely related 
paralogue the constitutive androstane receptor (CAR; NR13) and FXR. In addition, we 
link the activation of these nuclear receptors with activation of classical target genes for 
PXR, CAR and FXR, demonstrating that activation is both nuclear receptor- and statin-
specific. Finally, we present the novel finding that activation of a PXR reporter gene is 
regulated by FXR, demonstrating a feed forward pathway that is important in priming 
PXR-mediated responses to statins. 
Materials and Methods 
Reagents: Fugene-6 transfection reagent was purchased from Roche Diagnostics, 
Lewes, UK. Unless otherwise stated all other chemicals were of molecular biology grade 
and obtained from Sigma Chemical Co. (Poole, UK). The Huh7 human hepatocellular 
carcinoma cell line (Nakabayashi et al. 1982) was a kind gift from Dr Steve Hood (GSK, 
Ware, UK). All cells were routinely cultured in 75 cm2 vented tissue culture flasks (Nunc, 
 7 
 
UK) using minimal essential medium with Earle’s salts supplemented with 1 % non-
essential amino acids, 2 mM L-glutamine, 100U/ml penicillin, 100 µg/ml streptomycin 
and 10 % foetal bovine serum. All cell culture medium and supplements were 
purchased from Invitrogen (Paisley, UK). In order to maintain phenotypic consistency, 
Huh7 cells were only used for three weeks (approximately 6 passages) following 
recovery from liquid nitrogen. Expression plasmids for nuclear receptors were kindly 
provided as follows: PXR, Dr Kliewer (University of Texas, Dallas, USA); CAR, Prof M. 
Negishi (NIEHS, USA); FXR, Dr Swales (University of Surrey, UK. The IR6 reporter gene 
plasmid was also a kind gift of Dr Swales. The SLCO1B1 expression plasmid was 
constructed as follows: The coding sequence for SLCO1B1 (positions 120-2246 relative 
to the transcription start site) was amplified from Huh7-derived cDNA using a high 
fidelity polymerase (PrimeSTAR, Cambrex, UK). This product was cloned into the 
pTriEx1.1 expression plasmid (Clontech, UK) and sequenced to ensure 100% identity to 
the published sequence,   
In silico analysis: Ligand docking was undertaken using Autodock 4 suite and 
Autodock Tools for Windows (Morris et al. 2009). Molecular coordinates for the crystal 
structure of PXR with rifampicin bound (Chrencik et al. 2005) were obtained from the 
RCSB protein databank (Accession: 1SKX; http://www.rcsb.org/pdb/home/home.do), 
whereas three dimensional structures of statins were designed using  Corina 
(http://www.molecular-networks.com/products/corina). Docking was undertaken 
using a 0.375Å grid centred upon the ligand-binding pocket of PXR, using a genetic 
algortim with the following parameters: 150 iterations; 100 population size; 1E+6 
energy evaluations; 1E+5 maximum generations. Local search parameters were for 500  
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runs, with a maximum 3000 iterations. The output from each docking procedure was 
analysed using the Autodock Tools software. 
Reporter gene assay: Reporter gene assays were undertaken as described in Aouabdi 
et al (Aouabdi et al. 2006). Briefly, Huh7 cells were seeded into 96-well plates (Nunc 
International, Leicestershire, UK) at a concentration of 10,000 cells/well and incubated 
at 37 °C for 24 hrs in a humidified container for attachment.  FuGENE 6-mediated DNA 
co-transfections, using 75ng/well reporter gene constructs and 25ng/well over-
expression plasmid as appropriate, were performed as described previously (Goodwin 
et al. 1999), using serum-free medium for the six-hour transfection period; this was 
then replaced with fresh, complete medium, containing charcoal-stripped serum, for the 
remaining culture period.   
Transfections were allowed to proceed for 48 hours, in the presence or absence of 
xenobiotic as indicated, and then secretory alkaline phosphatase (SEAP) activity 
determined. Aliquots of cell culture medium (25 µl/well) were transferred into 96-well 
optiplates (Canberra Packard, UK). Endogenous alkaline phosphatase activity was 
deactivated by heat-treatment of the medium at 65 °C for 30 minutes. SEAP activity was 
then assayed using the AURORA system (ICN, Thame, UK), according to the 
manufacturer’s protocol. Chemiluminescent output was measured using a LumiCount 
automated plate reader (Canberra Packard, UK). SEAP activity following 48 hours 
culture was calculated for both reporter constructs and blank, control, plasmid, and a 
fold induction relative to vehicle control calculated. 
Nuclear Receptor Activation Assay. Nuclear reporter activation assays were 
undertaken using a modification of the Checkmate mammalian two-hybrid system 
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(Promega, UK). Initially, an extended ligand binding region for human PXR, CAR and 
FXR, representing amino acids 141-434,  162-348 and 250-469  respectively, was sub-
cloned into the pBIND expression plasmid, thus encoding a fusion construct with the 
GAL4-DBD. Next, Huh7 cells were seeded into 96-well plates (Nunc International, 
Leicestershire, UK) at a concentration of 20,000 cells/well and incubated at 37 °C for 24 
hrs.  FuGENE 6-mediated DNA co-transfections, using 25ng/well luciferase reporter 
plasmid (pG5luc) and 12.5ng/well NR-Gal4 fusion plasmid (pBIND-NR), using serum-
free medium for the six-hour transfection period; this was then replaced with fresh, 
complete medium, containing charcoal-stripped serum, for the remaining culture 
period. 
Transfections were allowed to proceed for 24 hours, in the presence or absence of 
xenobiotic as indicated, and then luciferase activity determined using the Dual-
Luciferase reporter system (Promega, UK) according to the manufacturer’s protocol. 
Luminescent output was measured using a LumiCount automated plate reader 
(Canberra Packard, UK).   
Transcript level measurement: Primers and TAMRA/FAM dual labelled probe specific 
for SLCO1B1 and 18S rRNA were designed using the Primer Express software (Applied 
Biosystems, Warrington, UK) and purchased from Eurofins (Wolverhampton, UK). 
Following knockdown and over-expression experiments, total RNA was isolated from 
quadruplicate samples using the RNeasy Mini kit (Qiagen) and quantified using a 
Nanodrop Agilent 2100 Bioanalyser. 
Total RNA was treated with RNase-free DNase (Promega, Southampton, UK) to remove 
genomic contamination. Reverse transcription was primed with random hexamers and 
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carried out by Superscript II (Invitrogen) as per the manufacturer’s instructions. To 
ensure that DNase treated samples were free from genomic contamination an RT- 
control (lacking enzyme) was carried out for every RNA sample. cDNA generated from 
50ng (SLCO1B1) or 50 pg (18S rRNA) of total RNA was amplified using TaqMan 
Universal PCR Master Mix with 400 nM primers and 200 nM fluorogenic probe in a total 
reaction volume of 25 μl. Q-PCR reactions were run on the ABI7000 SDS instrument and 
quantitation was carried out using the ABI proprietary software against a standard 
curve generated from human genomic DNA (Promega). 
Protein Level Measurement 
Plasma membrane protein extracts (10 µg per lane) were resolved on 12 % SDS-
polyacrylamide gels and then transferred electrophoretically to Hybond ECL 
nitrocellulose membranes (Amersham Biosciences, Little Chalfont, Bucks, UK).  
Membranes were blocked (1 hour) in 5 % fat free dried milk and then probed with 
primary antibodies against SLCO1B1 (sc-18433; 1:200; Autogen Bioclear, Calne, Wilts, 
UK) or β-actin (sc1616, 1:500; Autogen Bioclear) for one hour, followed by anti-goat  
(sc-2022; 1:20000) IgG  for one hour (Autogen Bioclear).  Bound antibodies were 
visualised using enhanced chemiluminescence reagents according to the manufactures 
instructions (Amersham Biosciences), and opposed to Fuji Super RX film (Fisher 
Scientific). 
Results and Discussion 
Differential activation of the nuclear receptors PXR, CAR and FXR by statins. 
Activation of CYP3A expression levels has been previously demonstrated for the statin 
class of chemicals, with this being enhanced by over-expression of the nuclear receptor 
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PXR (El-Sankary et al. 2001). However, both pravastatin and rosuvastatin are reported 
to be unable to induce CYP3A4 reporter gene activity, consistent with their lack of 
requirement for CYP3A-mediated metabolism prior to elimination. The reported lack of 
activation of CYP3A by rosuvastatin and pravastatin is consistent with these statins 
being poor agonists for PXR, despite their close structural similarity to other statins, 
although this has not been clearly demonstrated. To examine this, an in silico docking 
approach was undertaken, using Autodock to determine Gibbs energy for the most 
likely conformations of pravastatin, lovastatin and simvastatin docking into the PXR 
ligand binding domain. As expected, both lovastatin and simvastatin were able to dock 
efficiently into the ligand binding domain of PXR, with mean Gibbs energy values of -
11.5 kJ and -9.5 kJ for their most common conformations. Unexpectedly, pravastatin 
was also able to efficiently dock into the ligand binding domain of PXR, with a mean 
Gibbs energy for the most common conformation of -11 kJ, which is highly similar to 
that seen for both lovastatin and simvastatin. In addition, Figure 2A clearly 
demonstrates that the orientation of pravastatin allows allows acceptor/donor atoms to 
localise within  2Å of amino acids within the ligand binding pocket of PXR known to be 
central to ligand docking: Suitable within  of Ser247 (1.85Å), Gln285 (1.75Å) and 
His407 (2.12Å) (Ekins and Erickson 2002). 
As in silico analysis was not inconsistent with pravastatin being a ligand for PXR, 
despite its apparent lack of efficacy as a CYP3A inducer, we next examined this 
interaction in vitro. A fusion construct of the PXR LBD, plus activation domain, and the 
GAL4 DBD was generated and used to determine the ability of multiple statins to act as 
agonists against PXR. In addition, we examined for interaction of statins with CAR, a 
paralogue of PXR in higher mammals (Maglich et al. 2003) and FXR, another nuclear 
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receptor that has been implicated in statin-mediated responses (Habeos et al. 2005; 
Handschin and Meyer 2005; Rizzo et al. 2005). As can be seen from figure 2b, 
atorvastatin, fluvastatin, simvastatin (acid only) and lovastatin (both lactone and acid 
forms) are all able to elicit a statistically significant activation of PXR in a dose-
dependent manner. Activity of the lactone pro-drug may represent either real activity of 
this chemical form, or conversion to the pharmacologically active β–hydroxysteroid 
within the assay system. For the hydrophilic statins pravastatin and rosuvastatin, 
activation of PXR was less marked, although a significant, dose dependent, activation of 
PXR was observed with pravastatin (Figure 2a), consistent with the in silico docking. 
In general, statins were poor agonists of CAR, with significant activation of the ligand-
binding construct only occurring at the highest dose studied, if at all (Figure 2b): Only 
lovastatin (β-hydroxyacid) and rosuvastatin produced statistically significant, 
activations of the CAR ligand-binding assay, and then only at the highest dose tested 
(10µM), suggesting that this class of compounds are, generally, poor activators of CAR.  
Statin-mediated activation of the FXR fusion construct was observed with several of the 
tested statins, namely fluvastatin, lovastatin (acid), pravastatin and rosuvastatin; 
however, this activation was generally of lower potency than observed against PXR 
(Figure 2b). It is of note that both rosuvastatin and pravastatin were able to elicit 
significant activation of FXR within this system, again suggesting that these more 
hydrophilic statins may be nuclear receptor ligands.  
Statins demonstrate differential PXR-mediated target gene activation.  
CYP3A4 is a major drug metabolising enzyme in human liver, and is predominantly 
under the control of PXR, although other nuclear receptors may also influence the 
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transcription rate. It would hence be logical that those statins that are PXR agonists 
would also be activators of CYP3A4 transcription. To examine this, a reporter gene 
construct of the CYP3A4 regulatory regions (both proximal promoter and XREM) was 
transfected into the human hepatoma cell line Huh7, along with an expression plasmid 
for PXR, and challenged with a variety of statins, as well as the classical PXR and CAR 
agonists rifampicin and CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-
carbaldehyde O-(3,4-dichlorobenzyl)oxime) respectively. As can be seen from Figure 3, 
dose-dependent activation of the CYP3A4 reporter gene expression following exposure 
of Huh7 cells to atorvastatin, fluvastatin, lovastatin and simvastatin was demonstrated. 
In the case of lovastatin and simvastatin this activation was greater for the lactone pro-
drug compared to the active β-hydroxyacid, presumably reflecting increased cellular 
access of the lactone form, with subsequent activation representing either direct 
activity of this lactone, or the β-hydroxyacid formed following absorption of the lactone 
prodrug. No activation of the CYP3A4 reporter gene was evident in cells exposed to 
pravastatin or rosuvastatin. This difference between the ligand-activation and reporter 
gene assay results could be as a result of differential sensitivity between the two assays, 
or reflect that the agonism of PXR by pravastatin observed within the ligand binding 
assay was insufficient to elicit a transcriptional response of PXR-target genes.  This 
transcriptional response was shown to be PXR-dependent, as lack of co-transfection 
with the PXR expression plasmid let to an attenuated response (data not shown and (El-
Sankary et al. 2001)). The derived EC50 and Imax values for each of the statins against 
CYP3A4 reporter gene activation are presented in table 1. These data compare well to 
those previously reported, with statins showing Imax values in excess of the classical 
CYP3A4 inducing agent rifampicin (El-Sankary et al. 2001), suggesting that they are 
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potent activators of CYP3A4 expression in vitro. All dose response curves were fitted 
with a variable slope model, and the associated Hill slopes are given in table 1: These 
values are generally greater than one, suggesting co-operativity in the activation of the 
CYP3A4 reporter gene, which is perhaps not surprising given the multi-step nature of 
the induction pathway being measured herein, and could reflect nuclear receptor 
interactions.  
Whereas PXR is the main nuclear receptor responsible for transcriptional regulation of 
CYP3A4, other nuclear receptors are able to influence this control, either through 
binding to unique response elements (e.g. HNF4), or through response element sharing 
(e.g. CAR, VDR). The potent human-specific CAR agonist CITCO was able to activate 
CYP3A4 reporter gene expression, demonstrating that CAR-mediated regulation of 
CYP3A4 gene expression can occur in Huh7 cells in vitro (Figure 3). In comparison to 
the observed PXR-mediated effects on CYP3A4 transcription, only minimal CAR-
mediated activation of the CYP3A4 reporter gene by statins was observed.  A two-fold 
activation by atorvastatin, simvastatin (lactone) and lovastatin (lactone) was observed 
at the top dose examined (50µM), although these did not reach significance, whilst no 
increase in reporter gene expression was observed following exposure to simvastatin 
(acid), lovastatin (acid), pravastatin and rosuvastatin. Such data is consistent the 
findings of Kobayashi et al., who used a PBREM-based reporter construct, and observed 
a maximal two fold increase in reporter gene assay following exposure of HepG2 cells to 
30µM simvastatin, atorvastatin and fluvastatin, but no increase elicited by pravastatin 
(Kobayashi et al. 2005). Interestingly, in the same paper, PXR-mediated activations of a 
XREM reporter gene construct were, on average, an order of magnitude higher than 
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those seen with the CAR reporter construct, which is again consistent with the findings 
observed herein.  
Whereas the majority of statins posses a high degree of lipophillicity (logD7.0>1.5), both 
pravastatin (logD7.0=0.5) and rosuvastatin (logD7.5=0.5) are relatively hydrophilic, 
resulting in the requirement for SLCO-mediated uptake into hepatocytes (Hirano et al. 
2005; Holdgate et al. 2003; Ishigami et al. 2001): It is hence possible that the lack of 
activation of the CYP3A4 reporter gene by rosuvastatin and pravastatin may be due to 
lack of compound access. To examine this possibility, we modulated expression of 
SLCO1B1 (Figure 4), the main uptake transporter for pravastatin and rosuvastatin in 
hepatocytes (Ho et al. 2006; Nakai et al. 2001), and re-examined the impact of these 
statins on CYP3A4 reporter gene expression. Transfection of Huh7 cells with an 
expression plasmid encoding SLCO1B1 resulted in a statistically significant increase in 
SLCO1B1 at both the transcript and plasma membrane protein levels (figure 4a), 
consistent with the production of increased SLCO1B1 in the membrane, although this 
was not demonstrated to be functional. Increased levels of membrane-localised 
SCLO1B1 had no impact on CYP3A4 induction by either rifampicin or simvastatin, which 
is expected as neither of these compounds are substrates for SLCO1B1. In addition, no 
increased expression of the CYP3A4 reporter gene was observed with either pravastatin 
or rosuvastatin despite them being SLCO1B1 substrates (Figure 4b), suggesting that 
compound access was not the reason for the observed lack of response. However, 
further experimentation would be required to conclusively demonstrate that increased 
levels of membrane-localised SCLO1B1 do indeed increase pravastatin and rosuvastatin 
access into Huh7 cells. 
Statins demonstrate differential FXR-mediated target gene activation.  
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As demonstrated in Figure 2, statins are able to act as FXR agonists, albeit with 
generally lower potencies than against PXR. We, thus, examined the potential for 
activation of FXR-regulated target genes by statins through the use of an IR6 reporter 
gene construct in cells over-expressing FXR. As can be seen from figure 5a, fluvastatin, 
simvastatin and lovastatin were able to activate expression of the IR6 reporter gene 
plasmid, although with a lower potency than the classical FXR agonist chenodeoxycholic 
acid (CDCA); in comparison, rosuvastatin appeared to inhibit expression of the reporter 
gene construct at higher doses, an effect that was not due to toxicity (data not shown). 
For simvastatin and lovastatin, the lactone forms were more potent activators of the IR6 
reporter gene construct, consistent with the increased cellular access of this form 
compared to the β-hydroxyacid. This activation of the IR6-reporter gene is consistent 
with the agonist action of these statins against FXR (Figure 2), although no increase in 
FXR-mediated gene expression is seen for either rosuvastatin or pravastatin, despite 
their ability to agonise FXR in a ligand binding assay. This transcriptional response was 
shown to be FXR-dependent, as lack of co-transfection with an FXR expression plasmid 
let to an attenuated response (data not shown). Again, the use of an over-expression 
plasmid for SLCO1B1, the uptake transporter for rosuvastatin and pravastatin, was used 
to examine if lack of uptake was a limiting factors in reporter gene response. As can be 
seen from figure 5b, over-expression of SLCO1B1 did not increase allow IR6-reporter 
gene activation by rosuvastatin and pravastatin, suggesting that cellular uptake is not 
the limiting factor. 
It is becoming increasingly clear that nuclear receptors interact as part of a regulatory 
signal network, and it is through these interactions that the refinement of cellular 
response to chemical challenge may occur (Plant and Aouabdi 2009). Given that statins 
 17 
 
are able to act as agonists of both PXR and FXR, albeit with differing potencies, it is of 
interest to see if these two nuclear receptors interact at the transcriptional level. To 
examine this, we used a reporter gene construct containing the 2.2kb proximal PXR 
promoter, as described previously in Aouabdi et al (Aouabdi et al. 2006). As can be seen 
from figure 6, activation of FXR by the classical agonist CDCA was able to increase 
expression of the PXR reporter gene assay, demonstrating that FXR may regulate 
transcriptional activation of this PXR reporter gene. This effect was also seen with 
fluvastatin, simvastatin (lactone) and lovastatin (lactone), which were also able to 
activate the IR6-reporter gene, albeit at a relatively low level. Interestingly, in silico 
analysis of this proximal promoter region did not indicate the presence of an IR6 
element, to which FXR could bind and mediate its action; however, given that nuclear 
receptors are known to cross-talk at the level of response element selection, it is 
possible that FXR may be interacting through another site, with further experimentation 
being required to confirm this. Neither rosuvastatin nor pravastatin were able to 
significantly increase PXR reporter gene activity (Figure 5c). 
 
Conclusion 
The co-ordination of biological responses to xenobiotic insult represents a highly 
developed network designed to bring about the most efficient response to any given 
stimulus (Plant 2004). The central mediators of this response are, generally, members 
of the nuclear receptor superfamily, which number 48 in humans and regulate and 
whose gene products regulate a large number of anabolic and catabolic processes 
within the body (Bookout et al. 2006). It has been long established that cross-talk exists 
between nuclear receptors, both in terms of their ligand promiscuity (Ding and 
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Staudinger 2005; El-Sankary et al. 2001), activation of target genes (Maglich et al. 
2002), as well as cross-regulation of their own transcriptional regulation (Aouabdi et al. 
2006; Pascussi et al. 2003). As the networks of response to xenobiotic exposure become 
better delineated it can be seen that the relative levels of different nuclear receptors 
impacts upon the biological response elicited to any given stimuli (Bonofiglio et al. 
2005; Ding and Staudinger 2005). It is thus important to consider not only the presence 
of a putative target nuclear receptor within a tissue, but also the potential presence of 
other factors that may compete for the stimulating signal. We present herein an 
examination of the activation of PXR, CAR and FXR by the statin-group of nuclear 
receptor agonists, demonstrating that they capable of activating all three nuclear 
receptors, albeit to differing degrees.  Such information is important in determining the 
molecular actions following statin-exposure, and hence predicting the biological 
response observed. 
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Statin-tested EC50 (µM) Imax  Hill Slope 
Rifampicin 0.46±1.12 4.13±0.92 1.76 
Atorvastatin 1.95±2.17 15.44±1.17 3.75 
Fluvastatin 9.92±1.37 5.78±0.74 4.24 
Lovastatin – acid 26.85±1.42 3.04±0.72 6.59 
Lovastatin – lactone 1.86±2.06 6.48±0.76 2.04 
Simvastatin – acid 6.53±1.18 2.27±0.32 3.86 
Simvastatin - lactone 10.32±1.24 15.91±2.22 2.12 
Pravastatin Did Not Fit 
Rosuvastatin Did Not Fit 
 
Table 1: PXR-mediated activation of CYP3A4 reporter gene by statins 
CYP3A4 reporter gene expression was measured following 48 hours exposure to 
varying doses of indicated chemical (0-50µM) in the presence of a co-transfected PXR 
expression plasmid. A non-linear fit for log (agonist) vs response, variable slope, was 
undertaken using GraphPad Prism v5, generating EC50, maximal induction (Imax) and 
hill coefficient values
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Figure 1: Structures of statins used in the current study 
 
  
 Figure 2: Dose- and chemical
and CAR by statins. (A) Autodock
into the ligand binding domain of PXR (crystal structure of PXR  with
1SKX) using a genetic algorithm approach (150 GA runs). Pravastatin (
-specific agonism of the nuclear receptors PXR, FXR 
 4/ADT for Windows was used to dock pravastatin 
 rifampicin bound; 
 
26 
 
white) docking 
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overlapped rifampicin (dark grey) conformation, and produced donor/acceptor pairs 
with Ser247, Gln284 and His 407. (B) Nuclear receptor LBDs fused to the Gal4 DBD 
were used to examine statin-mediated activation of PXR, CAR and FXR. Each data point 
represents n=6, and statistical analysis was via one-way ANOVA; *=p<0.01, **=p<0.05 
and ***=p<0.001 relative to vehicle control. Graph is representative of triplicate repeat 
experiments. 
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Figure 3: Dose- and chemical-specific activation of CYP3A4 reporter gene 
expression by statins is dependent on PXR but not CAR. Huh7 cells were transiently 
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transfected with a SEAP reporter gene under the control of the CYP3A4 regulatory 
regions, plus either an expression plasmid for PXR or CAR, and then incubated with the 
indicated concentration of statin for 48 hours. SEAP activity was measured, corrected 
for transfection efficiency, and presented as fold induction relative to vehicle control. 
Each data point represents n=6, and statistical analysis was via one-way ANOVA; 
*=p<0.01, **=p<0.05 and ***=p<0.001 relative to vehicle control. Graph is 
representative of at least triplicate repeat experiments. 
 
  
 Figure 4: Over-expression of SLCO1B1 does not permit pravastatin
rosuvastatin-mediated activation of CYP3A4 
cells were transiently transfected with an expression plasmid for SLCO1B1 and 
incubated for 24 hours, whereupon RNA and protein l
Specificity of SLCO1B1 antibody was demonstrated by comparison to TNT
SLCO1B1. (B) Huh7 cells were transiently transfected with a SEAP reporter gene under 
the control of the CYP3A4 regulatory regions, plus expressio
SLCO1B1. Cells were then incubated 
corrected for transfection efficiency, and presented as fold induction relative to vehicle 
control. Each data point represents n=6, and statistical analysis was via one
reporter gene expression.
evels of SLCO1B1 were measured. 
n plasmids for FXR and 
with statin for 48 hours, SEAP activity measured, 
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- or 
 (A) Huh7 
-produced 
-way 
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ANOVA; ***=p<0.001 relative to vehicle control. Graph is representative of at least 
duplicate repeat experiments. 
 
  
 Figure 5:  Dose- and chemical
statins is dependent on FXR.  
a SEAP reporter gene under the 
expression plasmid for FXR alone, or (B) expression plasmids for FXR and SLCO1B1. 
Cells were then incubated with the indicated concentration of statin for 48 hours. SEAP 
activity was measured, corrected 
induction relative to vehicle control. Each data point represents n=6, and statistical 
-specific activation of an IR6-reporter gene by 
Six wells of Huh7 cells were transiently transfected with 
control of the [IR6]3 concatamer, plus either (A) an 
for transfection efficiency, and presented as fold 
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analysis was via one-way ANOVA; *=p<0.01, **=p<0.05 and ***=p<0.001 relative to 
vehicle control. Graph is representative of at least triplicate repeat experiments.  
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Figure 6: Dose- and chemical-specific activation of PXR reporter gene expression 
by statins is dependent on FXR. Six wells of Huh7 cells were transiently transfected 
with a SEAP reporter gene under the control of the PXR regulatory regions, plus an 
expression plasmid for FXR and then incubated with the indicated concentration of 
statin for 48 hours. SEAP activity was measured, corrected for transfection efficiency, 
and presented as fold induction relative to vehicle control. Each data point represents 
n=6, and statistical analysis was via one-way ANOVA; *=p<0.01 and ***=p<0.001 
relative to vehicle control. Graph is representative of at least triplicate repeat 
experiments. 
 
